Merrill maintains Myriad Genetics at buy

Myriad Genetics Inc: was kept at its buy rating by Merrill Lynch analyst David Munno. Data from the Flurizan in Alzheimer's disease suggested that patients on the 800 mg twice daily dose of Flurizan had improved global function, daily living scores and cognition relative to patients on lower doses or Flurizan or a placebo. Merrill continues to leave Flurizan out of its valuation analysis for Myriad, but if the drug works in phase 3 trials, it could be the only disease modifying drug for Alzheimer's, making it a probable blockbuster. Shares of the Salt Lake City biopharmaceutical company were up 77 cents, or 2.92%, at $27.16 on volume of 908,738 shares versus the three-month running average of 361,925 shares. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.